🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Glad for spending the last few days in Denver for Society for Immunotherapy of Cancer Spring Scientific. Lots of great talks, hopefully new ideas too. Bonus: my first poster, on MSI #ColorectalCancer ! Thanks Filippo Pietrantonio and Istituto Tumori for the opportunity

Meet the Author: Giovanni Randon, Medical Oncologist from Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, is 1st author of “Outcomes and a prognostic classifier in patients with MSI-high metastatic gastric cancer receiving PD-1 blockade,” recently published in #JITC! 1/6

👍🏾 MMC, cape and bev are safe and active in pseudomyxoma peritonei pts 🔭 Keeping an eye on KRAS inhibs and IO ♻️ Keep on addressing unmet needs in orphan diseases 🙏To everyone involved and to my mentor Filippo Pietrantonio @OncologyAdvance sciencedirect.com/science/articl…

Happy for the short trip to the beautiful València for ESMO preceptorship on Gastric Cancer! a few days with key leaders and many passionate fellows, incl. my friend Paolo Manca, and presented a clinical case! Thank you Lizzy Smyth @FlorianLordick and all ESMO - Eur. Oncology staff

Results from RELEVENT trial confirm the role of antiangionetic in TC. The best first plus chemo: ORR 80%, DCR 100%, PFS 18mo and OS 43mo. Good safety profile. 💥💥💥 Istituto Tumori and TYME network #ESMO23

#ESMO23 #crcsm 🏅Presidential Session 📣CODEBREAK300 Filippo Pietrantonio Ph3 sotorasib (960mg or 240mg)+pmab vs SOC in refractory #KRASG12C n=161 (2:1), mFU 7m ✅ mPFS LOREN 5.6m v 2.2m, HR 0.47 ✅ ORR LOREN 26.4% v 0% 🔸 OS not mature ➡️ sotorasib 960mg + p’mab is a promising

Wonderful weekend in Madrid. My very first #ESMO23 Heard great science, met brilliant oncologists… Here’s my friend Filippo Ghelardi and me: two very happy residents! ESMO - Eur. Oncology

Our work is out on ⁦JAMA Network Open⁩ ❗️ Is NALIRIFOX better than FOLFIRINOX as 1st line for metastatic #pancsm ❓ ❎similar OS and PFS, ⚠️different clinical and 💰 toxicity “I suppose we all thought that one way or another” jamanetwork.com/journals/jaman…

Biomarker based results of the academic italian ARMANI trial guided by INT GI oncology and presented by a splendid Giovanni Randon ESMO - Eur. Oncology #ESMOGI2024

First study assessing the activity and efficacy of BRAFi+EGFRi+/-MEKi in BRAFm dMMR/MSI-H #mCRC patients after progression to ICIs ❗️Come to have a look at our poster #66P in the foyer Many thanks to ESMO - Eur. Oncology for having awarded me a Merit Travel Grant to attend #ESMOGI24 🙏🏻

#ESMOGI24 has been incredible! ESMO - Eur. Oncology

INT squad at AIOM young oncologist congress AIOM Istituto Tumori

Sunitinib for the treatment of patients with advanced pheochromocytoma... sciencedirect.com/science/articl…

Don't miss #SUTNET ! An incredible 🇮🇹 effort led by Dr #Pusceddu Istituto Tumori with the powerful work of Dr Vincenzo Nasca Università degli Studi di Milano 🎓 just out on EORTC #EJC 📰 👉 on the role of sunitinib in #pheochromocytoma #rarecare #rarecancer Rare Cancers Europe 🦓🦓🦓 🎗️

Shorter ICI tx for dMMR/MSI-H mCRC isn't detrimental - may spare toxicities, costs and preserve QoL. Explore the findings from our study in Journal for ImmunoTherapy of Cancer & stay tuned for a future clinical trial on this question! Thx to my mentors and all the contributors! 🇫🇷🇮🇹🇪🇸🇺🇸

In this review we go through the key aspects that characterize MSI-H/dMMR cancers, in light of recent diagnostic advances and the successes of immune checkpoint inhibitors in both advanced and early stage disease. Have a look! nature.com/articles/s4157…